Biopharmx Corporatio (BPMX) 0.62 $BPMX BioPharmX

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biopharmx Corporatio (BPMX) 0.62 $BPMX

BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results for BPX-01 in Patients with Acne-Causing Bacteria
PR Newswire - Wed Jun 29, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced topline results from its Phase 2a safety study of BPX-01, a unique topical gel formulation of minocycline.
BPMX: 0.62 (unch)

BioPharmX to Report First Quarter Financial Results on June 14, 2016
PR Newswire - Tue Jun 07, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal first quarter ended April 30, 2016 after the close of trading on Tuesday, June 14, 2016. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PDT/4:30 p.m. EDT.
BPMX: 0.62 (unch)

BioPharmX Presents at American Congress of Obstetricians and Gynecologists (ACOG) Suggesting Molecular Iodine May be Effective, Non-hormonal Treatment for FBC
PR Newswire - Mon May 16, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, addressed a major ob-gyn meeting this weekend and encouraged the assessment of molecular iodine as a non-hormonal treatment for pain associated with fibrocystic breast condition (FBC) and a viable alternative to the current standard of care.
BPMX: 0.62 (unch)

BioPharmX to Present Research at Vitafoods Europe Showing that Molecular Iodine is Key to the Healthy Aging of Women's Breasts
PR Newswire Europe - Mon May 09, 6:02AM CDT
Company is one of a handful of presenters featured during the global conference
BPMX: 0.62 (unch)

BioPharmX Corporation Reports Fourth Quarter and Fiscal Year End Financial Results
PR Newswire - Tue Apr 26, 3:10PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the fourth quarter and fiscal year ended January 31, 2016.
BPMX: 0.62 (unch)

BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for Acne
PR Newswire - Mon Apr 25, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that it has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01.
BPMX: 0.62 (unch)

BioPharmX to Report Fourth Quarter and Full Year Financial Results on April 26, 2016
PR Newswire - Wed Apr 13, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal fourth quarter and full year ended January 31, 2016 after the close of trading on Tuesday, April 26, 2016. The company's management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
BPMX: 0.62 (unch)

Health Canada Approves BioPharmX Corporation Study of Violet® Iodine
PR Newswire - Mon Apr 04, 7:30AM CDT
BioPharmX engages KGK Synergize, Inc. to manage its Canadian phase 4 study for Violet molecular iodine breast health supplement
BPMX: 0.62 (unch)

BioPharmX Corporation Announces Closing Of $4.3 Million Public Offering
PR Newswire - Fri Apr 01, 10:45AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the closing of its previously announced underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock, with a public offering price of $1.20 per share and related warrant. The warrants have an exercise price of $1.20 per share, are exercisable immediately and expire on April 1, 2021. The transaction included participation from existing investors, including investment vehicles of Franklin Advisers.
BPMX: 0.62 (unch)

BioPharmX Corporation Announces Pricing Of Public Offering To Raise $4.3 Million
PR Newswire - Tue Mar 29, 8:16AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the pricing of an underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock with a public offering price of $1.20 for one share of common stock and a warrant to purchase 0.5 of a share of common stock. The company expects to receive gross proceeds of approximately $4.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The company has also granted the underwriters a 45 day option to purchase up to an additional 324,000 shares of common stock and/or warrants to purchase up to an additional 162,000 shares of common stock to cover over-allotments, if any.
BPMX: 0.62 (unch)

BioPharmX Corporation Announces Proposed Public Offering of Common Stock and Warrants
PR Newswire - Mon Mar 28, 3:05PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). BioPharmX intends to use the net proceeds of the offering for general corporate purposes, which may include funding research and development, increasing working capital, and acquisitions or investments in businesses, products, or technologies that are complementary to its own.
BPMX: 0.62 (unch)

BioPharmX Corporation Initiates Post-Market Phase IV Study for Fibrocystic Breast Condition (FBC) and Cyclic Mastalgia
PR Newswire - Tue Mar 22, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for use in dermatology and women's health, today announced it has received institutional review board (IRB) approval to initiate a Phase 4 study of its Violet® molecular iodine supplement for fibrocystic breast condition (FBC) and cyclic mastalgia.
BPMX: 0.62 (unch)

BioPharmX commences Phase 2 clinical study under U.S. FDA IND for BPX-01
PR Newswire - Thu Mar 03, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will immediately commence a Phase 2a clinical study under its U.S. FDA Investigational New Drug (IND) application for BPX-01, a hydrophilic formulation of the well-established drug minocycline. This clinical study will assess effectiveness in reducing the number of acne-causing bacteria in study patients at four weeks and evaluate the drug's safety and tolerability. This is the first clinical study in the clinical development program for BPX-01.
BPMX: 0.62 (unch)

BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directors
PR Newswire - Wed Jan 27, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that Craig A. Barbarosh has joined the company's board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee.
BPMX: 0.62 (unch)

BioPharmX's BPX-01 topical formulation may offer breakthrough in acne treatment
M2 - Mon Jan 18, 5:24AM CST
Pharmaceutical company BioPharmX (NYSE MKT: BPMX) said on Friday that its research shows that its unique formulation of minocycline, called BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.62 (unch)

Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
PR Newswire - Fri Jan 15, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at the 2016 Winter Clinical Dermatology Conference next week shows its unique formulation of minocycline, known as BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.62 (unch)

BioPharmX Violet Iodine Mobile Marketing Campaign On Pandora Achieves 25 Times the Average Industry Response
PR Newswire - Tue Jan 12, 7:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX) today announced that its preliminary campaign test results of advertising on Pandora (NYSE: P), the world's most powerful music discovery platform, show that personalized, streaming radio is an innovative, effective way to drive consumer awareness of Violet® iodine, a new breast health supplement for women.
P: 12.84 (+0.21), BPMX: 0.62 (unch)

Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.49 (unch), XRM: 7.05 (+0.31), TBBK: 5.72 (+0.17), BPMX: 0.62 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 119

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 378

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 0

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 259

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Dollar Tree's Earnings Drop and Future Outlook Challenges

Updated Category News Views 123

Highlights from Dollar Tree's Earnings Report Dollar Tree has encountered significant challenges in the market after revealing that its second-quarter earnings did not meet analysts' expectations. The discount retailer reported a year-over-year decline in net income, attributing this downturn to the considerable difficulties posed by the current economic conditions. This...

Continue Reading
The Risks of Banking Standards: A Deep Dive into Safety

Updated Category News Views 411

Understanding Current Banking Risks Banks are integral to the economy, ensuring that funds flow smoothly throughout various sectors. However, recent decisions to relax standards for banks have raised significant concerns about potential risks that may arise. Weiss Ratings, a prominent name in independent bank safety evaluations, has recently highlighted unsettling changes...

Continue Reading
Koch and OCP Forge Ahead with New Joint Venture

Updated Category News Views 46

Tying Two Giants Together When industrial titans like Koch Ag & Energy Solutions and Moroccan powerhouse OCP decide to double down on their existing partnership, anyone with a stake in iron and fertilizer industries ought to take note. It's not every day that two behemoth corporations decide to lace up together in a joint venture, signaling a potential shift in market...

Continue Reading
Youlife Group Inc. Moves to Expand with Strategic Acquisitions

Updated Category News Views 213

Youlife Group Inc. Expands Market Reach with Key Acquisitions Youlife Group Inc. (NASDAQ: YOU), recognized as a leading provider of blue-collar lifetime services, has exciting plans to make strategic acquisitions aimed at bolstering its market position. This initiative comes as Youlife enters into non-binding term sheets with the controlling shareholders of four notable...

Continue Reading
Advancements in Wet AMD Treatment: Outlook Therapeutics Updates

Updated Category News Views 326

Significant Milestones for Outlook Therapeutics ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pioneering biopharmaceutical company, has made notable strides towards securing regulatory approval for its innovative treatment for wet age-related macular degeneration (wet AMD). Their investigational product, ONS-5010 (bevacizumab-vikg), is an ophthalmic...

Continue Reading